POSACONAZOLE | A213454 | AET PHARMA US INC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from Aizant Drug Research Solutions Private Limited FDA-2024-P-4163 · 7 docket documents Aizant Drug Research Solutions Private Limited submitted this citizen petition under 21 CFR 10.25, 10.30, 314.122, and 314.161 requesting that the FDA determine whether the reference listed drug NOXAFIL (posaconazole) delayed-release tablets 1.2 g (NDA N205053), held by Merck Sharp and Dohme Corp, w | 505(q) | 2024-09-03 | Granted | Aizant Drug Research Solutions Private Limited |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$2.30
per ea
Lowest NADAC/Unit
$2.30
per ea
Brand NDCs
0
Generic NDCs
3
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 70748025807POSACONAZOLE DR 100 MG TABLET | $2.30 | EA | Generic | — | 2026-06-17 |
| 00904714904POSACONAZOLE DR 100 MG TABLET | $2.30 | EA | Generic | — | 2026-06-17 |
| 00904714910POSACONAZOLE DR 100 MG TABLET | $2.30 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.